Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Weight loss with tirzepatide was fairly uniform across different body mass index (BMI) ranges, ages, and number of obesity-related comorbidities in patients with overweight/obesity without type 2 ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...